216 related articles for article (PubMed ID: 36614261)
1. Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Brcic I; Kluba AM; Godschachner TM; Suppan C; Regitnig P; Dandachi N; Lax SF; Balić M
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614261
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and
Reznitsky FM; Jensen JD; Knoop A; Jensen MB; Laenkholm AV
Acta Oncol; 2023 Dec; 62(12):1913-1920. PubMed ID: 37961947
[TBL] [Abstract][Full Text] [Related]
3. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma.
Hoffmann LG; Sarian LO; Vassallo J; de Paiva Silva GR; Ramalho SOB; Ferracini AC; da Silva Araujo K; Jales RM; Figueira DE; Derchain S
Sci Rep; 2021 Nov; 11(1):22478. PubMed ID: 34795307
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer.
Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y
Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993
[TBL] [Abstract][Full Text] [Related]
8. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Ubago JM; Blanco LZ; Shen T; Siziopikou KP
Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
[TBL] [Abstract][Full Text] [Related]
10. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
11. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
14. Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer.
Deacu M; Tuţă LA; Boşoteanu M; Aşchie M; Mitroi AF; Nicolau AA; Enciu M; Cojocaru O; Petcu LC; Bălţătescu GI
Rom J Morphol Embryol; 2021; 62(1):63-71. PubMed ID: 34609409
[TBL] [Abstract][Full Text] [Related]
15. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Barroso-Sousa R; Barry WT; Guo H; Dillon D; Tan YB; Fuhrman K; Osmani W; Getz A; Baltay M; Dang C; Yardley D; Moy B; Marcom PK; Mittendorf EA; Krop IE; Winer EP; Tolaney SM
Ann Oncol; 2019 Apr; 30(4):575-581. PubMed ID: 30753274
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
